Company Performance - Viking Therapeutics, Inc. (VKTX) closed at $62.45, reflecting a -0.3% change from the previous day, underperforming the S&P 500's daily loss of 0.21% [1] - Over the past month, shares of Viking Therapeutics have appreciated by 2.98%, outperforming the Medical sector's loss of 3.28% but lagging behind the S&P 500's gain of 5.94% [1] Earnings Forecast - Viking Therapeutics is projected to report earnings of -$0.24 per share, indicating a year-over-year decline of 4.35% [2] Analyst Estimates - Recent changes to analyst estimates for Viking Therapeutics should be monitored, as positive revisions indicate analysts' confidence in the company's performance and profit potential [3] - The Zacks Consensus EPS estimate has decreased by 0.99% over the last 30 days, and Viking Therapeutics currently holds a Zacks Rank of 3 (Hold) [5] Industry Context - The Medical - Biomedical and Genetics industry, which includes Viking Therapeutics, ranks in the top 34% of all industries according to the Zacks Industry Rank, indicating a strong position within the sector [6]
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market